T-Cell NK-Cell Engaging Bispecific Antibodies Market

A Bispecific Antibodies is designed to bind two different targets or epitopes and can thereby exert two different functions. They are currently used to treat infectious, inflammatory, and malignant diseases.
T-Cell NK-Cell Engaging Bispecific Antibodies Market contains market size and forecasts of T-Cell & NK-Cell Engaging Bispecific Antibodies in global, including the following market information:
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Revenue, 2017-2022, 2023-2028, ($ millions)
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Sales, 2017-2022, 2023-2028, (K Units)
Global top five T-Cell & NK-Cell Engaging Bispecific Antibodies companies in 2021 (%)
The global T-Cell & NK-Cell Engaging Bispecific Antibodies market was valued at 485.7 million in 2021 and is projected to reach US$ 4927.4 million by 2028, at a CAGR of 39.2% during the forecast period 2022-2028.
The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028.
T-Cell Engagers Segment to Reach $ Million by 2028, with a % CAGR in next six years.
The global key manufacturers of T-Cell & NK-Cell Engaging Bispecific Antibodies include Amgen, Immunocore, Johnson & Johnson, Roche, Pfizer, AbbVie, MacroGenics and Regeneron, etc. In 2021, the global top five players have a share approximately % in terms of revenue.
MARKET MONITOR GLOBAL, INC (MMG) has surveyed the T-Cell & NK-Cell Engaging Bispecific Antibodies manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.
Total Market by Segment:
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Type, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Segment Percentages, by Type, 2021 (%)
T-Cell Engagers
NK-Cell Engagers
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market, by Application, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Segment Percentages, by Application, 2021 (%)
Hematological Cancers
Solid Tumors
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market, By Region and Country, 2017-2022, 2023-2028 ($ Millions) & (K Units)
Global T-Cell & NK-Cell Engaging Bispecific Antibodies Market Segment Percentages, By Region and Country, 2021 (%)
North America
US
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Benelux
Rest of Europe
Asia
China
Japan
South Korea
Southeast Asia
India
Rest of Asia
South America
Brazil
Argentina
Rest of South America
Middle East & Africa
Turkey
Israel
Saudi Arabia
UAE
Rest of Middle East & Africa
Competitor Analysis
The report also provides analysis of leading market participants including:
Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies revenues in global market, 2017-2022 (Estimated), ($ millions)
Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies revenues share in global market, 2021 (%)
Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies sales in global market, 2017-2022 (Estimated), (K Units)
Key companies T-Cell & NK-Cell Engaging Bispecific Antibodies sales share in global market, 2021 (%)
Further, the report presents profiles of competitors in the market, key players include:
Amgen
Immunocore
Johnson & Johnson
Roche
Pfizer
AbbVie
MacroGenics
Regeneron